for er positive patients with disease that is refractory to endocrine therapies , chemotherapy of choice includes either cmf ( cyclophosphamide , methotrexate , fluorouracil ) or fac ( fluorouracil , doxorubicin , cyclophosphamide ) , which is cmf with doxorubicin substituted for methotrexate .
C0010583
cyclophosphamide
C0950521
cmf